Prestige Consumer Healthcare (PBH) Non-Current Assets (2011 - 2025)
Prestige Consumer Healthcare's (PBH) quarterly Non-Current Assets came in at $3.1 billion in Q4 2025, up 3.69% year-on-year from $3.0 billion in Q4 2024, and up 3.95% quarter-over-quarter from $2.9 billion in Q3 2025.
Prestige Consumer Healthcare (PBH) Non-Current Assets (2011 - 2025) Analysis & Trends
Prestige Consumer Healthcare's Non-Current Assets history runs 15 years deep, the most recent figure standing at $3.1 billion for Q4 2025.
- On a quarterly basis, Non-Current Assets rose 3.69% year-over-year to $3.1 billion in Q4 2025; TTM through Dec 2025 was $11.9 billion, a 1.19% increase from a year earlier, with the FY2025 full-year figure at $3.0 billion, changed 0.36% from the prior year.
- Non-Current Assets advanced to $3.1 billion in Q4 2025 per PBH's latest filing, from $2.9 billion in the prior quarter.
- Across five years, Non-Current Assets topped out at $3.4 billion in Q4 2021 and bottomed at $2.9 billion in Q3 2024.
- The 5-year median for Non-Current Assets is $3.0 billion (2023), against an average of $3.1 billion.
- Across the five-year window, Non-Current Assets climbed 6.9% in 2022 and declined 12.3% in 2023, its largest moves.
- Year by year, Non-Current Assets stood at $3.4 billion in 2021, then dropped by 1.28% to $3.3 billion in 2022, then dropped by 11.82% to $2.9 billion in 2023, then advanced by 0.22% to $3.0 billion in 2024, then increased by 3.69% to $3.1 billion in 2025.
- Per Business Quant, the three latest PBH Non-Current Assets figures stand at $3.1 billion (Q4 2025), $2.9 billion (Q3 2025), and $3.0 billion (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 36.78 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 26.33 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 8.68 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 79.20 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 3.84 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 15.70 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 25.92 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 2.47 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 9.64 Bn |
| 10 | Prestige Consumer Healthcare | 2.34 Bn | 2.28 Bn | 157.37 Mn | 3.06 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.06 Bn |
| Sep 30, 2025 | 2.94 Bn |
| Jun 30, 2025 | 2.95 Bn |
| Mar 31, 2025 | 2.95 Bn |
| Dec 31, 2024 | 2.95 Bn |
| Sep 30, 2024 | 2.94 Bn |
| Jun 30, 2024 | 2.94 Bn |
| Mar 31, 2024 | 2.94 Bn |
| Dec 31, 2023 | 2.95 Bn |
| Sep 30, 2023 | 2.94 Bn |
| Jun 30, 2023 | 2.95 Bn |
| Mar 31, 2023 | 2.96 Bn |
| Dec 31, 2022 | 3.34 Bn |
| Sep 30, 2022 | 3.34 Bn |
| Jun 30, 2022 | 3.36 Bn |
| Mar 31, 2022 | 3.38 Bn |
| Dec 31, 2021 | 3.38 Bn |
| Sep 30, 2021 | 3.37 Bn |
| Jun 30, 2021 | 3.15 Bn |
| Mar 31, 2021 | 3.16 Bn |